Physio-Control nets monitor/defibrillator approval in Canada
Physio-Control, a wholly-owned subsidiary of Medtronic, has received approval by Health Canada to market the Lifepak 15 monitor/defibrillator within Canada.
The Redmond, Wash.-based Physio-Control was granted the CE Mark in January, certifying compliance with the European Union Medical Device Directive, and began its U.S. market release of the Lifepak 15 monitor/defibrillator in March.
The Lifepak 15 provides energy dosing up to 360 joules, and has various monitoring options available. The company also said its monitor/defibrillator integrates Masimo Rainbow Set Pulse CO-Oximetry technology for the noninvasive detection of carboxyhemoglobin (carbon monoxide in the blood) and methemoglobin in the blood (which may result from exposure to certain chemicals and drugs).
The Redmond, Wash.-based Physio-Control was granted the CE Mark in January, certifying compliance with the European Union Medical Device Directive, and began its U.S. market release of the Lifepak 15 monitor/defibrillator in March.
The Lifepak 15 provides energy dosing up to 360 joules, and has various monitoring options available. The company also said its monitor/defibrillator integrates Masimo Rainbow Set Pulse CO-Oximetry technology for the noninvasive detection of carboxyhemoglobin (carbon monoxide in the blood) and methemoglobin in the blood (which may result from exposure to certain chemicals and drugs).